Prader-Willi Syndrome Market is Projected to Grow Significantly by 2036 Owing to the Launch of Novel Hyperphagia Therapies and Advancements in Disease Management | DelveInsight

Posted on
by

Prader-Willi Syndrome Market is Projected to Grow Significantly by 2036 Owing to the Launch of Novel Hyperphagia Therapies and Advancements in Disease Management | DelveInsight
The Prader-Willi Syndrome (PWS) market is witnessing steady growth, driven by increasing disease awareness, improving diagnostic capabilities, wider adoption of growth hormone therapy, and rising demand for treatments targeting hyperphagia. The launch of new therapies and the advancement of promising pipeline candidates are expected to further strengthen the Prader-Willi Syndrome market during the forecast period.

DelveInsight, a leading market research firm, announces the release of its latest report, “DelveInsight’s Prader-Willi Syndrome (PWS) Market Insights, Epidemiology, and Market Forecast 2036.” This comprehensive report provides an in-depth understanding of Prader-Willi Syndrome, including historical and forecasted epidemiology, market trends, and treatment scenarios across the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom, and Japan.

Key Takeaways from the Prader-Willi Syndrome Market

  • The market size for Prader-Willi Syndrome in the leading markets is expected to grow significantly by 2036.

  • The 7MM Prader-Willi Syndrome market is projected to increase from approximately USD 619 million in 2022 to around USD 1.4 billion by 2036, reflecting robust market expansion during the forecast period.

  • DelveInsight’s analysis indicates that the diagnosed patient pool in the 7MM is expected to increase from approximately 24,600 patients in 2022 to more than 33,200 patients by 2036.

  • Based on DelveInsight’s assessment, the 7MM had approximately 26,000 diagnosed prevalent cases of PWS in 2025, with cases expected to increase owing to improved diagnostic capabilities, greater disease awareness, and expanding patient registries.

  • The United States accounted for the largest share of diagnosed prevalent cases in 2025, contributing approximately 47% of the total patient population across the seven major markets.

  • In the United States, nearly 70% of patients with Prader-Willi Syndrome are children, while children account for approximately 55% of the patient population in Japan.

  • The US FDA approved VYKAT XR (diazoxide choline) extended-release tablets in March 2025 for the treatment of hyperphagia in adults and children aged 4 years and older with Prader-Willi Syndrome, marking a significant advancement in disease management.

  • Leading Prader-Willi Syndrome companies, including Soleno Therapeutics, Harmony Biosciences, Aardvark Therapeutics, Palobiofarma, ConSynance Therapeutics, and others, are actively developing innovative therapies expected to reshape the treatment landscape in the coming years.

  • Promising Prader-Willi Syndrome therapies in clinical development include WAKIX (pitolisant), ARD-101, PBF-999, CSTI-500, HBS-102, and others.

Keen to know more about the market? Request our sample page athttps://www.delveinsight.com/sample-request/prader-willi-syndrome-market

Key Factors Driving the Prader-Willi Syndrome Market

Increasing Disease Awareness and Improved Diagnosis

Growing awareness of Prader-Willi Syndrome among healthcare professionals, improvements in molecular genetic testing, and expanding patient registries are facilitating earlier diagnosis and intervention. Enhanced screening and improved recognition of disease manifestations are expected to increase the diagnosed patient pool and support market growth.

Launch of Novel Therapies for Hyperphagia

The recent approval of VYKAT XR (diazoxide choline) represents a major milestone in the treatment of hyperphagia associated with Prader-Willi Syndrome. The availability of disease-specific therapy addressing one of the most debilitating symptoms of PWS is expected to significantly improve patient outcomes while expanding market opportunities.

Robust Late-stage Pipeline and Advancing Research

Multiple pharmaceutical companies are advancing innovative therapies targeting hyperphagia, excessive daytime sleepiness, behavioral symptoms, and appetite regulation. The continued clinical development of late-stage candidates such as WAKIX (pitolisant) and ARD-101 is expected to further transform the Prader-Willi Syndrome treatment landscape during the forecast period.

Prader-Willi Syndrome Competitive Landscape

The Prader-Willi Syndrome treatment landscape is evolving rapidly with the introduction of disease-specific therapies and a growing late-stage pipeline. VYKAT XR (diazoxide choline) from Soleno Therapeutics became the first FDA-approved therapy specifically indicated for the treatment of hyperphagia in adults and children aged four years and older with PWS following its approval in March 2025. Growth hormone therapies, including GENOTROPIN, NORDITROPIN, and OMNITROPE, continue to play an important role in managing growth failure and improving body composition, although they do not address hyperphagia or behavioral symptoms.

The pipeline remains highly active, with companies such as Harmony Biosciences, Aardvark Therapeutics, Palobiofarma, and ConSynance Therapeutics developing innovative therapies targeting diverse mechanisms, including histamine H3 receptor antagonism, extra-oral bitter taste receptor activation, and PDE-10 inhibition. These emerging candidates aim to address significant unmet needs in appetite control, behavioral symptoms, and overall disease management, positioning the Prader-Willi Syndrome market for substantial growth over the coming decade.

Discover more about therapies set to grab major Prader-Willi Syndrome market share @ Prader-Willi Syndrome Treatment Landscape

Recent Developments in the Prader-Willi Syndrome Market

  • In February 2026, Aardvark Therapeutics announced that the Institutional Review Board (IRB) approved an amended protocol for its ongoing Phase III HERO trial evaluating ARD-101 for hyperphagia in individuals with Prader-Willi Syndrome. The amended protocol lowers the minimum enrollment age from 10 years to 7 years, with topline data expected in Q3 2026.

  • In July 2025, Soleno Therapeutics presented new clinical data on VYKAT XR (diazoxide choline) at the ENDO 2025 Annual Meeting, highlighting the therapy’s continued clinical progress in patients with Prader-Willi Syndrome.

  • In May 2025, Soleno Therapeutics announced that the European Medicines Agency (EMA) validated its Marketing Authorization Application (MAA) seeking approval of VYKAT XR for the treatment of hyperphagia in adults and children aged 4 years and older with Prader-Willi Syndrome.

  • In March 2025, the US FDA approved VYKAT XR (diazoxide choline) extended-release tablets for the treatment of hyperphagia in adults and children aged 4 years and older with Prader-Willi Syndrome. Commercial launch followed in April 2025.

  • In April 2024, Harmony Biosciences initiated the global Phase III TEMPO trial evaluating WAKIX (pitolisant) for excessive daytime sleepiness and behavioral symptoms in patients aged 6 years and older with Prader-Willi Syndrome. According to the company’s 2025 corporate presentation, topline Phase III results are anticipated in 2026.

What is Prader-Willi Syndrome?

Prader-Willi Syndrome (PWS) is a rare, complex genetic neurodevelopmental disorder caused by the loss of expression of paternally inherited genes on chromosome 15q11-q13. The disorder is characterized by severe hypotonia during infancy, developmental delay, intellectual disability, endocrine abnormalities, behavioral challenges, and progressive hyperphagia that frequently leads to obesity if food intake is not strictly controlled.

Clinical management of PWS requires a multidisciplinary approach that includes growth hormone replacement therapy, nutritional management, behavioral interventions, physical and occupational therapy, hormone replacement, and supportive care. While growth hormone therapy improves growth, body composition, and physical performance, recent therapeutic advances have shifted attention toward treatments targeting hyperphagia, one of the most debilitating manifestations of the disease. Despite these advances, there is currently no cure for Prader-Willi Syndrome.

Prader-Willi Syndrome Epidemiology Segmentation

The Prader-Willi Syndrome epidemiology section provides insights into the historical and current Prader-Willi Syndrome patient pool and forecasted trends across the seven major markets. The Prader-Willi Syndrome market report provides epidemiological analysis for the study period 2022–2036, segmented into:

  • Total Prevalent Cases of Prader-Willi Syndrome

  • Total Diagnosed Prevalent Cases of Prader-Willi Syndrome

  • Age-specific Cases of Prader-Willi Syndrome

  • Genetic Subtype-specific Cases of Prader-Willi Syndrome

Scope of the Prader-Willi Syndrome Market Report

  • Therapeutic Assessment: Current marketed and emerging therapies for Prader-Willi Syndrome

  • Prader-Willi Syndrome Market Dynamics: Key market forecast assumptions, pricing trends, analogue assessment, therapy uptake, and market outlook

  • Key Companies: Soleno Therapeutics, Harmony Biosciences, Aardvark Therapeutics, Palobiofarma, ConSynance Therapeutics, Acadia Pharmaceuticals, and others

  • Key Therapies: VYKAT XR (diazoxide choline), GENOTROPIN, NORDITROPIN, OMNITROPE, WAKIX (pitolisant), ARD-101, PBF-999, CSTI-500, HBS-102, Tesomet, and others

  • Competitive Intelligence Analysis: SWOT analysis and Market Entry Strategies

  • Unmet Needs, KOL’s Views, Analyst’s Views, Prader-Willi Syndrome Market Access and Reimbursement

To know more about Prader-Willi Syndrome companies working in the treatment market, visit @ Prader-Willi Syndrome Clinical Trials and Therapeutic Assessment

Table of Contents

  • Prader-Willi Syndrome Market Report Introduction

  • Executive Summary for Prader-Willi Syndrome

  • SWOT Analysis of Prader-Willi Syndrome

  • Prader-Willi Syndrome Patient Share (%) Overview at a Glance

  • Prader-Willi Syndrome Market Overview at a Glance

  • Prader-Willi Syndrome Background and Overview

  • Prader-Willi Syndrome Epidemiology and Patient Population

  • Country-Specific Patient Population of Prader-Willi Syndrome

  • Prader-Willi Syndrome Current Treatment and Medical Practices

  • Prader-Willi Syndrome Unmet Needs

  • Prader-Willi Syndrome Emerging Therapies

  • Prader-Willi Syndrome Market Outlook

  • Country-Wise Prader-Willi Syndrome Market Analysis (2022–2036)

  • Prader-Willi Syndrome Market Access and Reimbursement of Therapies

  • Prader-Willi Syndrome Market Drivers

  • Prader-Willi Syndrome Market Barriers

  • Prader-Willi Syndrome Appendix

  • Prader-Willi Syndrome Report Methodology

  • DelveInsight Capabilities

  • Disclaimer

  • About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kirti Sharma
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/